Scientific Reports · 2021 · 10 citations · 16 references
Public HealthChronic Disease PreventionBehavioral Risk Factor ModificationImplementation SciencePharmaceutical ComplianceBlood Pressure ControlBlood Pressure ManagementHypertension ControlMedication AdherencePatient AdherenceTreatment AdherenceAdherence InterventionsBlood PressureControl Group DesignHealth Intervention EffectivenessLipid Profile ChangesMatched Control GroupMedication Adherence PromotionSystolic Blood Pressure
The PAM intervention is a behavioural intervention to support adherence to anti-hypertensive medications and therefore to lower blood pressure. This feasibility trial recruited 101 nonadherent patients (54% male, mean age 65.8 years) with hypertension and high blood pressure from nine general practices in the UK. The trial had 15.5% uptake and 7.9% attrition rate. Patients were randomly allocated to two groups: the intervention group (n = 61) received the PAM intervention as an adjunct to usual care; the control group (n = 40) received usual care only. At 3 months, biochemically validated medication adherence was improved by 20% (95% CI 3-36%) in the intervention than control, and systolic blood pressure was reduced by 9.16 mmHg (95% CI 5.69-12.64) in intervention than control. Improvements in medication adherence and reductions in blood pressure suggested potential intervention effectiveness. For a subsample of patients, improvements in medication adherence and reductions in full lipid profile (cholesterol 1.39 mmol/mol 95% CI 0.64-1.40) and in glycated haemoglobin (3.08 mmol/mol, 95% CI 0.42-5.73) favoured the intervention. A larger trial will obtain rigorous evidence about the potential clinical effectiveness and cost-effectiveness of the intervention.Trial registration Trial date of first registration 28/01/2019. ISRCTN74504989. https://doi.org/10.1186/ISRCTN74504989 .
16
Stephen S Lim, Theo Vos, Abraham D Flaxman et al. · The Lancet · 2012 · 12K citations · Full text
Public Health, Chronic Disease Control, Chronic Disease Prevention +17
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Michael Herdman, Claire Gudex, Andrew Lloyd et al. · Quality of Life Research · 2011 · 10K citations · Full text
Richard J. McManus, Jonathan Mant, Marloes Franssen et al. · The Lancet · 2018 · 419 citations · Full text
Maciej Tomaszewski, Christobelle White, Prashanth Patel et al. · Heart · 2014 · 403 citations · Full text
Medicine, Nephrology, Pharmacology +16